ArticleEuropean journal of clinical pharmacology2023
Will artificial intelligence chatbots replace clinical pharmacologists? An exploratory study in clinical practice.
Article in European journal of clinical pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Applying machine learning to pharmacovigilance data: A proof-of-concept study.British journal of clinical pharmacology · 2026Article
- Intelligent Framework for Adverse Drug Event Identification Using Large Language Models and Retrieval-Augmented Generation: Development and Evaluation Study.Journal of medical Internet research · 2026Article
- Large Language Models in Adverse Drug Reaction Detection and Pharmacovigilance: A Systematic Review of Current Applications, Challenges, and Future Directions.Diagnostics (Basel, Switzerland) · 2026Review
- Human vs. artificial intelligence: Physicians outperform ChatGPT in real-world pharmacotherapy counselling.British journal of clinical pharmacology · 2026Article
- Mapping applications and evaluations of LLM-enabled AI chatbots for health purposes: a scoping review.Frontiers in public health · 2026Article
- How is AI developing in pharmacovigilance?Therapeutic advances in drug safety · 2026Article
- Assessment of the Efficiency of a ChatGPT-Based Tool, MyGenAssist, in an Industry Pharmacovigilance Department for Case Documentation: Cross-Over Study.Journal of medical Internet research · 2025Article
- Artificial intelligence-powered chatbots in search engines: a cross-sectional study on the quality and risks of drug information for patients.BMJ quality & safety · 2025Article
- ChatGPT and oral cancer: a study on informational reliability.BMC oral health · 2025Article
- Can large language models detect drug-drug interactions leading to adverse drug reactions?Therapeutic advances in drug safety · 2025Article
- Evaluating the capability of ChatGPT in predicting drug-drug interactions: Real-world evidence using hospitalized patient data.British journal of clinical pharmacology · 2024Article
- Beyond the Scalpel: Assessing ChatGPT's potential as an auxiliary intelligent virtual assistant in oral surgery.Computational and structural biotechnology journal · 2024Article
- Article
- Editorial: Traditional and innovative approaches for signal detection.Frontiers in drug safety and regulation · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecently, there has been a growing interest in using ChatGPT for various applications in Medicine. We evaluated the interest of OpenAI chatbot (GPT 4.0) for drug information activities at Toulouse Pharmacovigilance Center.
methodsBased on a series of 50 randomly selected questions sent to our pharmacovigilance center by healthcare professionals or patients, we compared the level of responses from the chatbot GPT 4.0 with those provided by specialists in pharmacovigilance.
resultsChatbot answers were globally not acceptable. Responses to inquiries regarding the assessment of drug causality were not consistently precise or clinically meaningful.
conclusionThe interest of chatbot assistance needs to be confirmed or rejected through further studies conducted in other pharmacovigilance centers.
Indexed as
Identifiers
37566133What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.